D Mendes, A Averin, M Atwood, R Sato… - Expert Review of …, 2022 - Taylor & Francis
Objectives Despite the current pneumococcal vaccination program in England for older adults and adults with underlying conditions, disease burden remains high. We evaluated …
Background The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7) …
OK Fix, EA Blumberg, KM Chang, J Chu… - …, 2021 - Wiley Online Library
The aim of this document is to provide a concise scientific review of the currently available COVID‐19 vaccines and those in development, including mRNA, adenoviral vectors, and …
KM Shea, J Edelsberg, D Weycker… - Open forum …, 2014 - academic.oup.com
Background. Although it is widely accepted that adults with immunocompromising conditions are at greatly increased risk of pneumococcal infection, the extent of risk among …
E Backhaus, S Berg, R Andersson, G Ockborn… - BMC infectious …, 2016 - Springer
Background Incidence, manifestations and case-fatality rate (CFR) of invasive pneumococcal disease (IPD) vary with age and comorbidities. New vaccines, changing age …
Abstract Background/Aims In April 2010 the 7-valent pneumococcal conjugate vaccine (PCV7) was replaced by the 13-valent PCV. We investigated pneumococcal carriage in …
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine …
The proportion of the global population aged 65 and older is rapidly increasing. Infections in this age group, most recently with SARS-CoV-2, cause substantial morbidity and mortality …
Background Community-acquired pneumonia (CAP) is one of the most common acute infections associated with a substantial clinical and economic burden. There have been few …